Evaluator Training and Reliability for SMA Global Nusinersen Trials1

Background: Training methodology was established to optimize reliability of outcome measures in the nusinersen clinical trials. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Hammersmith Functional Motor Scale Expanded (HFMSE), and Revised Upper Limb (RULM) were primary or secondary outcomes. Methods: Video review, quarterly conference calls, and item scoring checks supported evaluator competence. Baseline and screening along with video review established intra and inter-rater reliability. Results: Inter and intra-rater reliability were both excellent. Intraclass correlation coefficients (ICC) ranged between 0.906–0.994 across initial training meetings and 0.824–0.996 across annual retraining meetings. This was similar for CHOP INTEND (ICC = 0.824–0.951), HFMSE (ICC = 0.981–0.996), and RULM (ICC = 0.966–0.990). Intra-rater reliability for the CHOP INTEND, HFMSE, and RULM were ICC = 0.895 (95% CI: 0.852–0.926; n = 116), ICC = 0.959 (95% CI: 0.942–0.971; n = 125), and ICC = 0.948 (95% CI: 0.927–0.963; n = 126) respectively. Conclusions: Rigorous evaluator training ensures reliability of assessment of subjects with spinal muscular atrophy (SMA) in multicenter international trials.

[1]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[2]  R. Finkel,et al.  Revised upper limb module for spinal muscular atrophy: Development of a new module , 2017, Muscle & nerve.

[3]  R. Finkel,et al.  Interim Results of a Phase 2 Clinical Study of Nusinersen (ISIS-SMNRx) in Patients with Infantile-Onset Spinal Muscular Atrophy (P5.004) , 2016 .

[4]  Jacqueline Montes,et al.  Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy , 2016, Neurology.

[5]  B. Darras Spinal muscular atrophies. , 2015, Pediatric clinics of North America.

[6]  W. Chung,et al.  Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[7]  W. Chung,et al.  Prospective cohort study of spinal muscular atrophy types 2 and 3 , 2012, Neurology.

[8]  Y. Hua,et al.  Antisense-based therapy for the treatment of spinal muscular atrophy , 2012, The Journal of cell biology.

[9]  W. Chung,et al.  Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III , 2011, Journal of child neurology.

[10]  R. Finkel,et al.  The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability , 2010, Neuromuscular Disorders.

[11]  R. Finkel,et al.  An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients , 2007, Neuromuscular Disorders.

[12]  J. Weir Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. , 2005, Journal of strength and conditioning research.